Entity

Time filter

Source Type


Zhou R.,Tianjin Medical University | Yu T.,Tianjin Medical University | Feng C.,The First Hospital of Qinhuangdao City | Ma L.,Tianjin Medical University | And 2 more authors.
Chinese Journal of Lung Cancer | Year: 2011

Background and objective DWI-MRI could detect the microscopic motion of water molecules which is sensitive to microcirculation change of many kinds of tumors after therapy. The aim of this study is to investigate the value of diffusion-weighted imaging (DWI) in monitoring and predicting lung cancer response to chemotherapy. Methods Nineteen patients pathologically diagnosed as lung cancer were included in this study, all of whom received both conventional MRI and DWI examinations one week before and one month after the initiation of chemotherapy. The response of lung cancers to therapy were classified into four groups: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) based on the change of lesion diameter measured on axial T2-weighted MR imaging. Apparent diffusion coefficients (ADCs) were measured for each lesion at pre- and post-chemotherapy and were compared with t-test. The correlations between the percentage changes of ADCs and the percentage changes of diameters (long, short, and mean) were further evaluated with Pearson correlation coefficient, as well as that between pre-chemotherapy ADCs and the percentage changes of diameters. Results The mean pre-chemotherapy ADCs was significantly higher than that of the post-chemotherapy ADCs (1.482 ± 0.456 vs 1.675±0.485, P=0.004). A positive correlation was found between the percentage changes of ADCs and the percentage changes of the long, short, and the mean diameter, respectively (r=0.635, r=0.612, r=0.539, P<0.05). A negative correlation was found between pre-chemotherapy ADCs and the percentage change of the long diameter after chemotherapy in PR and SD group (r=-0.806, r=-0.632, P<0.05). Conclusion The change of ADCs can sensitively reflect the early change of lung cancer response to chemotherapy and has the potential ability to dynamically monitor the lung cancer response to chemotherapy combined with the morphological measurement. Source


Peng Y.,Yanshan University | Fu Z.-Z.,The First Hospital of Qinhuangdao City | Gao L.-M.,The First Hospital of Qinhuangdao City | Di Y.,The First Hospital of Qinhuangdao City
Asian Pacific Journal of Cancer Prevention | Year: 2014

Background: The objective was to study the effect of Scutellaria baicalensis Georgi ethanol extracts (SBGE) on immune and anti-oxidant function in U14 tumor-bearing mice. Materials and Methods: U14 tumor-bearing mice were randomly divided into eight groups: a control group, a cyclophosphamide (CTX) group, three dose groups of SBGEI (high, medium, low), and three dose groups of SBGEII (high, medium, low). After two weeks, the thymus and spleen weight indices of mice bearing U14 cervical cancer were calculated. Enzyme linked immunosorbent assays (ELISA) was used to determine the levels of serum IL-2, TNF-α, IL-8, and PCNA. MDA activity and SOD activity in plasma were measured with detection kits. Results: In the SBGE groups, thymus weight and spleen weight indices of U14 tumor-bearing mice were significantly higher than in the control group or CTX group (p < 0.05). Compared to control group, the levels of serum IL-2 and TNF-α in U14 tumor-bearing mice increased significantly, whereas the contents of serum IL-8 and PCNA decreased (p < 0.05). The activity of SOD increased with the growing dose of SBGE, while the activity of MDA decreased significantly in the higher-dose groups of SBGE. Conclusions: These findings suggested that SBGE, especially at high dose, 1000 mg/kg, showed significant immune and anti-oxidant effects infU14 tumor-bearing mice, which might be the mechanisms of SBGE inhibition of tumor growth. Source


Fu B.-H.,The First Hospital of Qinhuangdao City | Fu Z.-Z.,The First Hospital of Qinhuangdao City | Meng W.,Hebei North University | Gu T.,The First Hospital of Qinhuangdao City | And 2 more authors.
Tumor Biology | Year: 2015

We examined the levels of platelet vascular endothelial growth factor (VEGFPLT) and serum level of transforming growth factor beta 1 (TGF-β1) in non-small cell lung cancer (NSCLC) patients before and after chemotherapy to assess their clinical value as biomarkers. A total of 115 subjects were recruited at the First Hospital of Qinhuangdao between July 2012 and October 2013, including 65 NSCLC patients receiving chemotherapy (NSCLC group) and 50 healthy controls (control group). All NSCLC patients received gemcitabine plus cisplatin (GP regimen) for a total of two courses. VEGFPLT and serum TGF-β1 levels were measured before and after chemotherapy using enzyme-linked immunosorbent assay (ELISA). Platelet count was obtained using the Abbott CD-1600 auto blood analyzer. NSCLC group was categorized into complete response (CR) plus partial response (PR) group and stable disease (SD) plus progressive disease (PD) group based on the results of CT scans obtained 1 week after chemotherapy. Our results revealed that VEGFPLT and serum TGF-β1 levels were significantly higher in NSCLC group before chemotherapy, compared to the control group (VEGFPLT, 0.813 ± 0.072 vs. 0.547 ± 0.024; t = 26.48; P < 0.001 and TGF-β1, 46.00 ± 4.47 vs. 16.43 ± 2.12; t = 44.87; P < 0.001). Importantly, VEGFPLT and serum TGF-β1 levels decreased significantly after chemotherapy in CR + PR group in comparison with before chemotherapy (VEGFPLT, 0.453 ± 0.078 vs. 0.814 ± 0.127; t = 15.51; P < 0.001 and TGF-β1, 20.17 ± 2.43 vs. 42.13 ± 4.54; t = 27.31; P < 0.001). By contrast, VEGFPLT and serum TGF-β1 levels were markedly higher after chemotherapy in the SD + PD group in comparison with before chemotherapy (VEGFPLT, 0.816 ± 0.043 vs. 1.065 ± 0.016; t = 22.38; P < 0.001 and TGF-β1, 41.80 ± 5.46 vs. 45.83 ± 4.62; t = 2.32; P = 0. 03). Our results show that NSCLC patients exhibit high VEGFPLT and serum TGF-β1 levels, and VEGFPLT and TGF-β1 levels correlate with chemotherapy response to GP regimen. Therefore, VEGFPLT and serum TGF-β1 levels are valuable biomarkers in clinical monitoring of NSCLC patients. © 2015, International Society of Oncology and BioMarkers (ISOBM). Source

Discover hidden collaborations